This finding has critical clinical implications, underlining that targeting EZH2 methyltransferase activity by EZH2 inhibitors might not yield inhibitory efficacies in this setting, whereas targeting the downstream effector FAK with a clinically applicable kinase inhibitor could block EZH2-induced breast cancer bone metastasis, as was shown in mouse models [209]. Here, EZH2 is linked to breast carcinoma.